New Data Shows Bristol Meyers Squib’s Zeposia Improves Cognitive Outcomes in Multiple Sclerosis Patients

Results from Bristol Meyers Squib’s (BMS) Phase 3 DAYBREAK and SUNBEAM trials show that Zeposia helps improve and preserve cognitive abilities in the majority of relapsing remittent multiple sclerosis (MS) patients. The effects were most pronounced in patients with high thalamic volume. Cognitive dysfunction is a common problem for MS patients that greatly impacts quality of life.

According to Jonathan Sadeh, MD, MSc, senior VP of Immunology and Fibrosis Development at BMS, “At Bristol Myers Squibb, we’re committed to pathbreaking science in multiple immune-mediated diseases with the goal of alleviating the symptoms and disease progression experienced by individuals suffering from these illnesses and, ultimately, elevating the standard of care. We’re excited by the potential effect of Zeposia in protecting cognitive function when used early in treatment before brain volume is lost and what it can mean for individuals with relapsing multiple sclerosis”

To learn more, click here.

(Source: Business Wire, June 24^th, 2022)